Coherus BioSciences, Inc. financial statements, including revenue, expenses, profit, and loss
The total revenue of CHRS for the last quarter is 91.52 M USD, and it's 22.74% higher compared to the previous quarter. The net income of Q4 23 is -79.65 M USD.